ARTICLE | ANTI-AGEING MEDICINE |
Genotypes and risk of breast cancer Gene/Allele
CYP1A1*2A* CYP1B1*3*
CYP17A1
(T34C)* GSTM1*
GSTT1* SULT1A1*2* COMT (V158M)*
ER (Xbal)* ER (Pvull)*
wt/wt wt/vt vt/vt X
X X
X X X X
xx PP
Genotype wt/wt: homozygous wild type wt/vt: heterozygous variant genotype vt/vt: homozygous variant genotype
Predictive activity N normal slightly increased increased strongly increased
slightly decreased decreased strongly decreased no activity
by obesity, alcohol consumption, insulin resistance,
and ageing. Alcohol consumption in particular, when combined with HRT, synergistically increases the risk of breast cancer24, 25
. Ageing and menopause, a high body
mass index (BMI), and the presence of inflammatory cytokines TNF-α, IL-1 and IL-6, increase the aromatase activity that converts androgens into oestrogens, increasing a local source of oestrogens that facilitates the growth of hormone responsive tumour cells. Oestrogen dominance as a result of hormonal imbalances between oestrogen, progesterone and testosterone can further complicate the oestrogen burden. Nutritional factors and dietary oestrogens can
influence receptor expression and modify SNP activity, affecting the detoxification pathways of oestrogen. This is a foundation of nutrigenetics that is used in patients with an unfavourable oestrogen metabolism genetically determined to modulate and improve detoxification.
Genetic testing for increased HRT safety and personalised prevention Testing low penetrance genes involved in oestrogen metabolism are useful diagnostic tools to identify a patientÕs individual metabolic pathways, and to calculate the possible risk for breast cancer, as well as allowing physicians to tailor a personalised approach to HRT. None of these polymorphisms would significantly increase the risk of breast cancer on their own, but in the presence of prolonged oestrogen exposure or other
44 ❚ September 2012 |
prime-journal.com Certain
nutrients can selectively alter gene expression involved in oestrogen metabolism, modifying the type and amount of oestrogen metabolites.
Figure 5 Combination of genotypes GSTM1 and COMT with an increased risk for sporadic breast cancer (predictive activity of enzymes, absent and decreased)
N N
N
N
N
*Non-accepted parameter, carried out according to the Good Practice Guide of Analyses
relevant dietary and lifestyle risk factors, the risk for breast cancer is significantly increased26, 27
Genotype Predictive activity
. Furthermore, a
combination of certain polymorphisms can increase the incidence of breast cancer (e.g. COMT in combination with GSTM1) (Figure 5). Laboratoires R• unis (Luxemburg) provides a
comprehensive genetic test (FEMgen) that can help to obtain a clear picture of SNPs present in a particular case, as well as their predictive activity. This test should be used as an additional tool to blood and urine samples (for oestrogen metabolites), medical history, lifestyle and diet. In cases of a presence of a combination of high-risk genotypes, a hormone substitution therapy will not be prescribed: not conventional HRT, and not even bioidentical HRT (BHRT; which is considered safer and more efficacious than synthetic counterparts)28
. In fact,
dietary and lifestyle changes, and botanicals as supplementation, would be prescribed to decrease the risk of hormone-sensitive cancers. This is often given for minimally- to moderately-increased risks where the decision to prescribe BHRT is made on the basis of favourable oestrogen metabolism determined by genetic testing, a good 2-OH : 16α-OH ratio, absence of oestrogen dominance, and a balanced oestrogen : progesterone ratio.
Nutrigenetics to modulate oestrogen metabolism Certain nutrients can selectively alter gene expression involved in oestrogen metabolism, modifying the type and amount of oestrogen metabolites. The aim is to enhance production of protective metabolites in order to safely prescribe BHRT. Once genetic testing is complete, there is a protocol for the application of nutrigenetics. Nutritional therapy can be used to balance oestrogen in the body and to deal with excess oestrogen from all resources as following: ■ Promote a healthy ratio of phase I oestrogen metabolites (2-OH : 16α-OH estrone)
■ Protect cells from Phase I oestrogen metabolites
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84